Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Endothelial fate mapping in mice with pulmonary hypertension.

Qiao L, Nishimura T, Shi L, Sessions D, Thrasher A, Trudell JR, Berry GJ, Pearl RG, Kao PN.

Circulation. 2014 Feb 11;129(6):692-703. doi: 10.1161/CIRCULATIONAHA.113.003734.

2.
3.

Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension.

White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB.

Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L583-90.

4.

Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats.

Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN.

Am J Respir Crit Care Med. 2002 Nov 15;166(10):1403-8.

PMID:
12406854
5.

Characterization of proximal pulmonary arterial cells from chronic thromboembolic pulmonary hypertension patients.

Quarck R, Wynants M, Ronisz A, Sepulveda MR, Wuytack F, Van Raemdonck D, Meyns B, Delcroix M.

Respir Res. 2012 Mar 27;13:27. doi: 10.1186/1465-9921-13-27.

6.

Cellular fibronectin and von Willebrand factor concentrations in plasma of rats treated with monocrotaline pyrrole.

Schultze AE, Emeis JJ, Roth RA.

Biochem Pharmacol. 1996 Jan 26;51(2):187-91.

PMID:
8615888
7.

Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells.

Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN.

Circulation. 2003 Sep 30;108(13):1640-5.

8.

Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension.

Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB.

Circulation. 2004 Sep 14;110(11):1499-506.

9.

ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats.

Li G, Liu Y, Zhu Y, Liu A, Xu Y, Li X, Li Z, Su J, Sun L.

Lung. 2013 Aug;191(4):327-36. doi: 10.1007/s00408-013-9470-8.

PMID:
23652350
10.

Dichloroacetate prevents but not reverses the formation of neointimal lesions in a rat model of severe pulmonary arterial hypertension.

Li B, Yan J, Shen Y, Liu Y, Ma Z.

Mol Med Rep. 2014 Oct;10(4):2144-52. doi: 10.3892/mmr.2014.2432.

PMID:
25110234
11.

Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles.

Chen D, Zhou D, Qian J, Chen F, Guan L, Dong L, Ge J.

Exp Lung Res. 2012 Sep;38(7):333-43. doi: 10.3109/01902148.2012.702852.

PMID:
22888849
12.

Syngeneic bone marrow mononuclear cells improve pulmonary arterial hypertension through vascular endothelial growth factor upregulation.

Yoshida H, Kitaichi T, Urata M, Kurobe H, Kanbara T, Motoki T, Kitagawa T.

Ann Thorac Surg. 2009 Aug;88(2):418-24. doi: 10.1016/j.athoracsur.2009.04.105.

PMID:
19632386
13.

Monocrotaline pyrrole interacts with actin and increases thrombin-mediated permeability in pulmonary artery endothelial cells.

Wilson DW, Lamé MW, Dunston SK, Taylor DW, Segall HJ.

Toxicol Appl Pharmacol. 1998 Sep;152(1):138-44.

PMID:
9772209
14.

Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension.

Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD.

Am J Pathol. 1997 Oct;151(4):1019-25.

15.

Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.

Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, Al-Omran M, Cherng WJ, Li RK, Stanford WL, Verma S.

Circulation. 2004 Mar 23;109(11):1392-400.

16.
17.

Caveolin-1 expression during the progression of pulmonary hypertension.

Huang J, Wolk JH, Gewitz MH, Mathew R.

Exp Biol Med (Maywood). 2012 Aug;237(8):956-65. doi: 10.1258/ebm.2012.011382.

PMID:
22890027
19.

Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured rats.

Kass DJ, Rattigan E, Kahloon R, Loh K, Yu L, Savir A, Markowski M, Saqi A, Rajkumar R, Ahmad F, Champion HC.

PLoS One. 2012;7(4):e35388. doi: 10.1371/journal.pone.0035388.

20.

The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.

Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14.

PMID:
16896805

Supplemental Content

Support Center